Ratajczak, A., M. Szulińska, and P. Bogdański, Agoniści GLP-1 dla lekarzy praktyków. Forum Zaburzeń Metabolicznych, 2014. 5(4): p. 165-171. https://journals.viamedica.pl/forum_zaburzen_metabolicznych/article/view/40783

Strojek, K., Układ inkretynowy w cukrzycy typu 2: patofizjologia i możliwości terapii. Kreo 2011: p. 71−83.

Farilla, L., et al., Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets. Endocrinology, 2003. 144(12): p. 5149-5158. https://academic.oup.com/endo/article/144/12/5149/2880380?login=false DOI: https://doi.org/10.1210/en.2003-0323

Tilinca, M.C., et al., A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review. Medicina (Kaunas), 2021. 57(7). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307742/ DOI: https://doi.org/10.3390/medicina57070669

Trujillo, J.M., W. Nuffer, and B.A. Smith, GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab, 2021. 12: p. 2042018821997320. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953228/ DOI: https://doi.org/10.1177/2042018821997320

Singh, S., et al., Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab, 2017. 19(2): p. 228-238. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299485/ DOI: https://doi.org/10.1111/dom.12805

Vilsbøll, T., et al., Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Bmj, 2012. 344: p. d7771. https://www.bmj.com/content/344/bmj.d7771 DOI: https://doi.org/10.1136/bmj.d7771

Garvey, W.T., et al., Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care, 2020. 43(5): p. 1085-1093. https://diabetesjournals.org/care/article/43/5/1085/35698/Efficacy-and-Safety-of-Liraglutide-3-0-mg-in DOI: https://doi.org/10.2337/dc19-1745

Marso, S.P., et al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 2016. 375(4): p. 311-22. https://www.nejm.org/doi/full/10.1056/nejmoa1603827 DOI: https://doi.org/10.1056/NEJMc1611289

Marso, S.P., et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 2016. 375(19): p. 1834-1844. DOI: https://doi.org/10.1056/NEJMoa1607141

Gerstein, H.C., et al., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, 2019. 394(10193): p. 121-130. https://www.sciencedirect.com/science/article/abs/pii/S0140673619311493

Kanie, T., et al., Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013650. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812344/ DOI: https://doi.org/10.1002/14651858.CD013650.pub2

Hasanzad, M., et al., A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity. J Diabetes Metab Disord, 2020. 19(2): p. 1863-1872. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843728/ DOI: https://doi.org/10.1007/s40200-020-00619-9

International Diabetes Federation. IDF Diabetes Atlas—9th Edition. DiabetesAtlas.

Zheng, Y., S.H. Ley, and F.B. Hu, Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, 2018. 14(2): p. 88-98. https://www.nature.com/articles/nrendo.2017.151 DOI: https://doi.org/10.1038/nrendo.2017.151

Apovian, C.M., J. Okemah, and P.M. O’Neil, Body Weight Considerations in the Management of Type 2 Diabetes. Advances in Therapy, 2019. 36(1): p. 44-58. https://link.springer.com/article/10.1007/s12325-018-0824-8 DOI: https://doi.org/10.1007/s12325-018-0824-8

Association, A.D., 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care, 2020. 44(Supplement_1): p. S111-S124. https://diabetesjournals.org/care/article/44/Supplement_1/S111/31020/9-Pharmacologic-Approaches-to-Glycemic-Treatment DOI: https://doi.org/10.2337/dc21-S009

Marre, M., et al., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med, 2009. 26(3): p. 268-78. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871176/ DOI: https://doi.org/10.1111/j.1464-5491.2009.02666.x

Russell-Jones, D.V., A.A.; Schmitz, O.; Sethi, B.K.; Lalic, N.; Anti´c, S.; Zdravkovic, M.; Ravn, G.M.; Simo, R. , On behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009. Diabetologia 2009. 52. https://link.springer.com/article/10.1007/s00125-009-1472-y DOI: https://doi.org/10.1007/s00125-009-1472-y

Alsugair, H.A., et al., Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis. Healthcare (Basel), 2021. 9(9). https://www.mdpi.com/2227-9032/9/9/1125 DOI: https://doi.org/10.3390/healthcare9091125

Iepsen, E.W., S.S. Torekov, and J.J. Holst, Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther, 2015. 13(7): p. 753-67. https://www.tandfonline.com/doi/abs/10.1586/14779072.2015.1054810 DOI: https://doi.org/10.1586/14779072.2015.1054810

Chou, C.A. and S.F. Chuang, Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients. J Diabetes Investig, 2020. 11(6): p. 1524-1531. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610111/ DOI: https://doi.org/10.1111/jdi.13314

Lean, M.E., et al., Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet, 2018. 391(10120): p. 541-551. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33102-1/fulltext DOI: https://doi.org/10.1016/S0140-6736(17)33102-1

Lean, M.E.J., et al., Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol, 2019. 7(5): p. 344-355. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30068-3/fulltext

Abd El Aziz, M., et al., Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab, 2020. 22(4): p. 699-704. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.13924 DOI: https://doi.org/10.1111/dom.13924

Holst, J.J., Incretin hormones and the satiation signal. Int J Obes (Lond), 2013. 37(9): p. 1161-8. https://www.nature.com/articles/ijo2012208 DOI: https://doi.org/10.1038/ijo.2012.208

Haining Wang MD, Y.L.M., Qing Tian MD,Jin Yang MD,Ran Lu MD,Siyan Zhan PhD,Jari Haukka PhD,Tianpei Hong MD, Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018. 20. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.13177 DOI: https://doi.org/10.1111/dom.13177

Nauck, M., et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 2009. 32(1): p. 84-90. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606836/ DOI: https://doi.org/10.2337/dc08-1355

Sfairopoulos, D., et al., Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones, 2018. 17(3): p. 333-350. https://link.springer.com/article/10.1007/s42000-018-0038-0 DOI: https://doi.org/10.1007/s42000-018-0038-0

Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 2017. 377(1): p. 13-27. https://www.nejm.org/doi/full/10.1056/nejmoa1614362 DOI: https://doi.org/10.1056/NEJMoa1614362

Bąk-Sosnowska M., B.M., et.all., Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2022 – stanowisko Polskiego Towarzystwa Leczenia Otyłości. . Med. Prakt. , 2022(wyd. specj.;): p. 1–87. https://ptlo.org.pl/aktualnosci/209-pdf__zalecenia_kliniczne_dotyczace_postepowania_u_chorych_na_otylosc_2022

Zhong, P., et al., Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine, 2022. 75(3): p. 718-724. https://link.springer.com/article/10.1007/s12020-021-02945-1 DOI: https://doi.org/10.1007/s12020-021-02945-1

Zhang, P., et al., The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. Afr Health Sci, 2019. 19(3): p. 2591-2599. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040262/ DOI: https://doi.org/10.4314/ahs.v19i3.35

Barboza, J.J., et al., Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med, 2022. 11(11). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181568/ DOI: https://doi.org/10.3390/jcm11112998

EMA. European public assessment report (EPAR) for Saxenda. 2015; Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda.

Rubino, D.M., et al., Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Jama, 2022. 327(2): p. 138-150. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753508/ DOI: https://doi.org/10.1001/jama.2021.23619

O'Neil, P.M., et al., Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet, 2018. 392(10148): p. 637-649. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31773-2/fulltext DOI: https://doi.org/10.1016/S0140-6736(18)31773-2

Salcedo, I., et al., Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British Journal of Pharmacology, 2012. 166(5): p. 1586-1599. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419902/ DOI: https://doi.org/10.1111/j.1476-5381.2012.01971.x

Yildirim Simsir, I., U.E. Soyaltin, and S. Cetinkalp, Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease. Diabetes Metab Syndr, 2018. 12(3): p. 469-475. https://www.sciencedirect.com/science/article/abs/pii/S1871402117304782?via%3Dihub DOI: https://doi.org/10.1016/j.dsx.2018.03.002

Hölscher, C., Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Neuropharmacology, 2018. 136(Pt B): p. 251-259. https://www.sciencedirect.com/science/article/abs/pii/S0028390818300406?via%3Dihub DOI: https://doi.org/10.1016/j.neuropharm.2018.01.040

Darsalia, V., et al., Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology, 2018. 136(Pt B): p. 280-286. https://pubmed.ncbi.nlm.nih.gov/28823610/ DOI: https://doi.org/10.1016/j.neuropharm.2017.08.022

Detka, J. and K. Głombik, Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacol Rep, 2021. 73(4): p. 1020-1032. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413152/ DOI: https://doi.org/10.1007/s43440-021-00274-8

Gong, N., et al., Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci, 2014. 34(15): p. 5322-34. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608999/ DOI: https://doi.org/10.1523/JNEUROSCI.4703-13.2014

Sharma, A. and S. Verma, Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Can J Diabetes, 2020. 44(1): p. 93-102. https://www.canadianjournalofdiabetes.com/article/S1499-2671(19)30658-6/fulltext DOI: https://doi.org/10.1016/j.jcjd.2019.09.003

Cena, H., L. Chiovato, and R.E. Nappi, Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab, 2020. 105(8): p. e2695-709. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457958/ DOI: https://doi.org/10.1210/clinem/dgaa285

Newsome, P.N., et al., A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med, 2021. 384(12): p. 1113-1124. https://www.nejm.org/doi/full/10.1056/NEJMoa2028395 DOI: https://doi.org/10.1056/NEJMoa2028395

MZ: braki leku Ozempic spowodowane przepisywaniem pacjentom poza wskazaniami rejestracyjnymi. 2022; Available from: https://pulsmedycyny.pl/mz-braki-leku-ozempic-spowodowane-przepisywaniem-pacjentom-poza-wskazaniami-rejestracyjnymi-1165886.

Australian Government, T.D.o.H.a.A.C., Therapeutic Goods Administration. The current Ozempic (semaglutide) supply situation. 2022 4 November 2022]; Available from: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/ozempic-semaglutide-shortage.

FDA. Current and Resolved Drug Shortages and Discontinuations Reported to FDA, 2022; Available from: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm.